<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868695</url>
  </required_header>
  <id_info>
    <org_study_id>ID 2020-00322</org_study_id>
    <nct_id>NCT04868695</nct_id>
  </id_info>
  <brief_title>SUBJECTIVE AND OBJECTIVE OUTCOME OF ENDOSCOPIC SINUS SURGERY IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS</brief_title>
  <official_title>SUBJECTIVE AND OBJECTIVE OUTCOME OF ENDOSCOPIC SINUS SURGERY IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      (A): Beidseitige Fronto-Spheno-Ethmoidektomie mit Erweiterung des natürlichen Zuganges zur&#xD;
      Stirnhöhle (Draf Typ II): Unter einem Draf Typ II Zugang versteht man die Erweiterung des&#xD;
      natürlichen Zuganges zur Stirnhöhle mit Entfernung des Bodens der Stirnhöhle zwischen der&#xD;
      Lamina papyracea zur Augenhöhle und der mittleren Nasenmuschel.&#xD;
&#xD;
      (B): Beidseitige Fronto-Spheno-Ethmoidektomie mit maximaler Erweiterung des Zuganges zur&#xD;
      Stirnhöhle (Draf Typ III): Unter einem Draf Typ III verste. (C) Beidseitige&#xD;
      Spheno-Ethmoidektomie: Abtragung des Processus uncinatus, die Eröffnung der Kieferhöhle, die&#xD;
      Eröffnung des vorderen und hinteren Siebbeinsystems und die Eröffnung der Keilbeinhöhle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (A): Beidseitige Fronto-Spheno-Ethmoidektomie mit Erweiterung des natürlichen Zuganges zur&#xD;
      Stirnhöhle (Draf Typ II): Unter einem Draf Typ II Zugang versteht man die Erweiterung des&#xD;
      natürlichen Zuganges zur Stirnhöhle mit Entfernung des Bodens der Stirnhöhle zwischen der&#xD;
      Lamina papyracea zur Augenhöhle und der mittleren Nasenmuschel.&#xD;
&#xD;
      (B): Beidseitige Fronto-Spheno-Ethmoidektomie mit maximaler Erweiterung des Zuganges zur&#xD;
      Stirnhöhle (Draf Typ III): Unter einem Draf Typ III verste. (C) Beidseitige&#xD;
      Spheno-Ethmoidektomie: Abtragung des Processus uncinatus, die Eröffnung der Kieferhöhle, die&#xD;
      Eröffnung des vorderen und hinteren Siebbeinsystems und die Eröffnung der Keilbeinhöhle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal Polyp Score</measure>
    <time_frame>12 months</time_frame>
    <description>Nasal Polyps</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>CRS</condition>
  <arm_group>
    <arm_group_label>Bilateral Spheno-Ethmoidectomy:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Draf Typ 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3</intervention_name>
    <description>1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3</description>
    <arm_group_label>Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b</arm_group_label>
    <arm_group_label>Bilateral Spheno-Ethmoidectomy:</arm_group_label>
    <arm_group_label>Draf Typ 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic CRSwNP patients without improvement after conservative treatment for at&#xD;
             least 6 months Extent of disease at least Davos Polyp Score ≥ 4 points Age 18-65 years&#xD;
             Signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous sinunasal surgery High resolution paranasal sinus CT shows other pathology&#xD;
             (e.g. mucocele) Incapable of judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael B Soyka, MD</last_name>
    <phone>0432531460</phone>
    <email>rhinologie@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Meerwein, MD</last_name>
    <phone>0432531460</phone>
    <email>rhinologie@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zurich University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Soyka, Dr.med.</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>michael.soyka@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Soyka, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

